Synairgen's R&D costs creep up as it focuses on lead product
This article was originally published in Scrip
The respiratory drug discovery company Synairgenis keeping a tight rein on its finances over the next year, as it focuses on the clinical trial it recently started with its lead programme, inhaled interferon beta, in development to prevent exacerbations of asthma and chronic obstructive pulmonary disease.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.